Charleston News Online

The Intravenous Immunoglobulin (IVIG) Market is anticipated to increase during the study period (2017-2030)

The Intravenous Immunoglobulin (IVIG) Market is anticipated to increase during the study period (2017-2030)

August 19
11:16 2021
The Intravenous Immunoglobulin (IVIG) Market is anticipated to increase during the study period (2017-2030)
Intravenous Immunoglobulin Market
The IVIG market dynamics are expected to shift as companies around the world, including Evolve Biologics, Biotest, Momenta Pharmaceuticals, Green Cross Pharma, Octapharma, Takeda, Grifols, and others, work tirelessly to develop new IVIG options to treat a variety of indications, including PIDD, chronic ITP, CIPD, and others.

DelveInsight’s Intravenous Immunoglobulin market report offers comprehensive coverage of the current treatment practices, emerging drugs, Intravenous Immunoglobulin market share of individual therapies, and current and forecasted Intravenous Immunoglobulin market Size from 2017 to 2030, segmented into 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan).

Some of the Important Findings from the Intravenous Immunoglobulin Market Report

  • According to the “Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee,” the two main uses for Intravenous Immunoglobulin, are as replacement therapy for primary or acquired antibody deficiency disorders and as immunomodulatory agents in patients with autoimmune or inflammatory diseases.

  • According to the British NHS’s Ig Database Report, neurologic indications are currently leading the world in Intravenous Immunoglobulin consumption, followed by PID and hemato-oncology consumption.

  • According to Gelfand’s article, approximately 25–30% of IVIG used in the United States is still used as replacement therapy for Primary Immunodeficiency Disease (PID).

  • Key players, such as Evolve Biologics, Biotest, Momenta Pharmaceuticals, Green Cross Pharma, Octapharma, Takeda, Grifols, CSL Behring, Kedrion Biopharma, and others are thoroughly working toward the development of new IVIG options to treat a wide array of indications such as PIDD, chronic ITP, CIPD, and others.

  • Momenta Pharmaceuticals’ M254 is an enzymatically sialylated IVIG product. It is currently being studied in a four-part Phase I/II study.

  • PlasmaCap IG (Evolve Biologics) is a 10% liquid formulation Intravenous immune globulin (IVIG) product made from plasma sourced in the United States. The product is indicated for replacement therapy in patients two years of age and older with Primary Immune Deficiency Diseases (PIDD).

  • Biotest is testing BT595 in a multicenter, open-label, prospective study to determine the clinical efficacy, safety, and pharmacokinetic properties of normal human immunoglobulin for intravenous administration as replacement therapy in patients with Primary Immunodeficiency Disease (PID).

Request for the sample to know more about IVIG @ Intravenous Immunoglobin Therapy for Autoimmune Disease

The Intravenous Immunoglobulin market report also covers current Intravenous Immunoglobulin treatment practice/algorithm, Intravenous Immunoglobulin market drivers, Intravenous Immunoglobulin market barriers, and unmet medical needs. 

Intravenous Immunoglobulin: Overview

Intravenous immunoglobulin (IVIG) is a product made up of antibodies that can be administered intravenously. IVIG has traditionally been used as replacement therapy for patients who have primary or secondary immunoglobulin deficiencies. However, IVIG is increasingly being used (at higher doses than for replacement therapy) in certain bacterial or viral infectious diseases.

Intravenous Immunoglobulin Epidemiology Segmentation

The Intravenous immunoglobulin report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:

  • Intravenous immunoglobulin Targeted Indications Total Incident/Prevalent Cases 

  • Intravenous immunoglobulin Indication-Specific Utilization

  • Number of Patients Eligible for Intravenous immunoglobulin 

Intravenous Immunoglobulin Therapeutics Market

As the number of cases of chronic conditions increases, so does the demand for plasma protein therapies for the treatment of rare and chronic conditions. At present, the US Food and Drug Administration has approved only a few indications for the use of IVIG. IVIG is used as off-label for a variety of other indications. Some of the FDA-approved IVIG product drugs used to treat several indications include Gamimune (for primary immunodeficiency), GAMUNEX-C (for CIDP), Gammaplex (for primary immunodeficiency and chronic immune thrombocytopenia (ITP) in adults), Octagam (for chronic ITP in adults), Privigen (for adults with CIDP), and others.

Intravenous Immunoglobulin Market

The dynamics of the IVIG market are expected to change as companies around the world such as  Evolve Biologics, Biotest, Momenta Pharmaceuticals, Green Cross Pharma, Octapharma, Takeda, Grifols, and others are working tirelessly to develop new IVIG options to treat a wide range of indications including PIDD, chronic ITP, CIPD, and others.

Get a detailed analysis of the IVIG therapy market @ Intravenous Immunoglobin Market Share

Intravenous Immunoglobulin Pipeline Therapies and Key Companies 

  • PlasmaCap IG  10%: Evolve Biologics

  • BT595: Biotest

  • M254: Momenta Pharmaceuticals

  • GC5101B: Green Cross Pharma

Table of Contents

1.

Report Introduction

2.

Executive Summary of IVIG 

3.

SWOT Analysis of IVIG 

4.

IVIG: Patient Share (%) Overview at a Glance

5.

IVIG: Market Overview (%) at a Glance

6.

IVIG Disease Background and Overview 

7.

IVIG Epidemiology and Patient Population

8.

Country-specific Patient Population of IVIG 

9.

IVIG Current Treatment and Medical Practices

10.

Patient Journey

11.

IVIG Unmet Needs

12.

IVIG Key Endpoint of Clinical Trials

13.

IVIG Marketed Products

14.

IVIG Emerging Therapies

15.

Conjoint Analysis of IVIG Therapies

16.

IVIG: Market Size of 7MM

17.

IVIG Country-Wise Market Analysis (2017–2030)

18.

Market Access and Reimbursement of IVIG Therapies

19.

IVIG Market drivers

20.

IVIGMarket barriers

21.

Appendix

22.

DelveInsight Capabilities

23.

Disclaimer

24.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Chronic Inflammatory Demyelinating Polyneuropathy Market

Get comprehensive historical and forecast analysis of Chronic Inflammatory Demyelinating Polyneuropathy Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as CSL Behring, CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

About Author

admin

admin

Related Articles